Alexander Titus, Ph.D., is an AI and biotechnology executive focused on building the systems required to translate scientific capability into real-world impact. He works at the intersection of technology, national security, and the life sciences, with a career spanning the private sector, government, and academia.Titus currently leads the Vigilance Division at Alloy Therapeutics, where he is building new approaches to ensuring that critical capabilities, countermeasures, and capital are available when they are needed most. Previously, Titus served as the inaugural Vice President of AI and Machine Learning at Avidity Biosciences, where he built and led the company’s first enterprise AI organization and platform, driving transformation across research, clinical development, regulatory, and commercial functions. Before that, he was Vice President of Strategy and Computational Sciences at Colossal Biosciences, where he helped launch new ventures and scale AI-driven capabilities across the organization.During the COVID-19 pandemic, Titus was at Google Cloud, leading AI and life sciences solutions for the global public sector. His government service includes serving as the inaugural Assistant Director for Biotechnology within the Office of the CTO at the U.S. Department of Defense, where he led the development of the Department’s first biotechnology modernization strategy.He is the founder of In Vivo Group and The Connected Ideas Project, where he writes and advises on the co-evolution of technology, policy, and society. Across his career, he has also held AI research fellowships with Amazon, In-Q-Tel, and within the U.S. Intelligence Community.Titus holds a Ph.D. in Quantitative Biomedical Sciences from Dartmouth College and dual undergraduate degrees in biochemistry and biology from the University of Puget Sound.